The long arm of the law: Canadian court orders offshore gambling site to block Manitoba users

By May M. Cheng and Alexander Watts

This article was originally published on Law360 Canada on July 18, 2025, 11:05 AM EDT .
You can read the original article here.

In a wake-up call for digital platforms offering online gaming services to Canadian consumers, a provincial court in Manitoba has issued a decision blocking a service provider for violating Canadian gambling laws.

In Manitoba Liquor and Lotteries Corp. v. IL Nido Ltd., 2025 MBKB 89, a well-known online entertainment and gambling platform was enjoined from operating in the province of Manitoba and ordered to use geo-blocking technology to prevent users in the province from accessing its services.

This is a stark reminder that online gaming remains highly regulated in Canada and foreign entities operating online must still comply with local laws.

Background Facts

The applicant, the Manitoba Liquor and Lotteries Corporation (MBLL), is Manitoba’s exclusive provider of lotteries, including online gambling products and services. MBLL is subject to both federal and provincial regulatory frameworks, and the profits from all gambling services are used to fund government-sponsored programs in the province that benefit Manitobans.

The respondent, Il Nido Ltd., is incorporated in Antigua and Barbuda and operates the websites Bodog.eu and Bodog.net; the first offers real-money gambling services, including betting on various sporting events or table and casino games, and the latter offers free versions under the same branding. A second respondent, Sanctum IP Holdings Ltd., owns the Canadian trademark registration for BODOG. Neither of the respondents responded to MBLL’s application or participated in the proceedings.

Violations of Canadian Law

Under sections 202 and 206 of the Criminal Code, all gambling in Canada is prohibited unless it falls within a statutory exception that is typically reserved for provincial authorities. The respondent’s Bodog.eu and .net platforms were accessible to Manitoba residents, but were not authorized or licensed to operate in Manitoba under Canadian law. The MBLL therefore sought an injunction to prohibit the respondents from offering unauthorized gambling services in Manitoba.

In addition, the MBLL sought an injunction under the Competition Act and Trademarks Act for falsely claiming that Bodog was a legal website in Canada. MBLL alleged that the respondents’ promotional materials violated:

  • section 52(1) of the Competition Act (by making false or misleading representations), and
  • section 7(d) of the Trademarks Act (by advertising false or misleading descriptions likely to deceive the public).

MBLL claimed that the respondents  misrepresented the lawfulness, character and quality of the Bodog platforms to deliberately mislead Manitobans by misrepresenting that:

  • “Bodog is a legal online casino in Canada”
  • Bodog is “one of the safest places to gamble online within the realms of the country”; and 
  • “Bodog is the most trusted site in Canada”

Manitoba Court of King’s Bench decision

The court found that the respondents knowingly made materially false representations to promote their business and services in Canada, in violation of s. 52(1) of the Competition Act. By advertising their platforms as legal and trustworthy for the purposes of attracting players in Manitoba, the respondents misled customers and engaged in conduct harmful to both the public and MBLL, including by diverting profits from online gaming outside the province.

The court also held that the respondents violated s. 7(d) of the Trademarks Act by using demonstrably false representations regarding lawfulness trustworthiness and safety of the online platforms in Manitoba. The court held that the demonstrably false representations used in association with the respondent’s trademark diminished the goodwill of MBLL’s marks and contributed to reputational harm.

Permanent injunction granted

Recognizing the limited ability to enforce monetary judgements against offshore entities, the court concluded that injunctive relief was the only effective remedy. The court also held that there was no impediment to exercising its discretion to grant the permanent injunction, citing the framework in Google Inc. v. Equustek Solutions Inc., 2017 SCC 34 at para. 66. Having found that MBLL’s legal rights were established, that damages were inadequate, and that no alternative remedy was available, the court granted a permanent injunction that included the following relief:

  • Prohibiting the respondents from operating or advertising their Bodog.eu and Bodog.net platforms in Manitoba;
  • Requiring that the respondents use geo-0blocking to prevent Manitoba residents from accessing their websites and gambling services; and
  • Restraining the respondents from using advertising to target Manitoba residents across digital and traditional media.

Importantly, the court noted the permanent injunction was narrowly tailored to target only unlawful conduct in Manitoba and relied on technology the respondents already had employed to geo-block the services.

Conclusion

It would seem that the resurgence of online gaming that took place during the pandemic is now facing a reckoning as legitimate Canadian gaming authorities take on foreign actors targeting the pocketbooks of Canadian residents. While legitimate Canadian gaming authorities intensify efforts to crack down on unauthorized platforms, businesses offering online gambling or related services should treat this case as a cautionary precedent. Claims about legality, safety or legitimacy must be truthful, verifiable and clearly tailored to avoid misleading the public; companies would be well advised to regularly review their advertising, trademark use and technological safeguards to ensure compliance. As the digital marketplace continues to evolve, this case signals that any business targeting Canadian consumers must operate within the bounds of Canadian law, or risk significant consequences. 

 

 

Show Me the Money—Later? The Ins and Outs of Taxation Considerations in Earn-Outs Structures

By Gregory M. Prekupec & Rahul Gupta

What happens when a buyer and seller cannot agree on how much a business is worth? One approach is for the seller to walk away from the deal with the hope a new buyer will agree with their valuation. To avoid the inefficiency which stems from this route, the parties can agree to an “earn-out” or “reverse earn-out” to bridge any gaps which may exist between the buyer and seller parties. Despite the reconciliatory nature of this approach, one must be made aware of its tax implications before pursuing it.

An earn out is a conditional payment of the purchase price which is subject to the corporation achieving certain metrics within a specified time-frame post closing. For instance, if the corporation achieves a certain EBITA threshold for the first three years after the acquisition. If the target achieves these targets, the seller receives the balance of the purchase price, as specified by the underlying purchase agreement. Otherwise, the funds flow back to the purchaser. In a reverse earn out scenario, the inverse is true. If the target does not achieve certain milestones, the seller returns a portion of the purchase price back to the purchaser.

In addition to the above, earn-outs/reverse earn-outs can also serve as a useful tool for each of the following scenarios:

A. Market or industry volatility;

B. The target is engaged in an experiential or novel venture (e.g., a new style of restaurant); or

C. The purchaser is unable to secure adequate financing to fund the acquisition.

The primary tax considerations for a seller in an earn-out or reverse earn-out scenario is whether the earn-out payments are treated as capital gains or ordinary income. Sellers prefer such payments to be treated as capital gains as only 50% of the amount received (i.e., the gain) is included in the seller’s taxable income; whereas, ordinary income treatment includes 100% of the payment in the same. Generally speaking, the Canada Revenue Agency’s view on the tax treatment of an earn-out can be based on how the transferred property is being used. Asset-based deals can reduce the risk of ordinary income treatment as income is being derived from the use of an asset, rather than ownership of a business (i.e., shares).

Novel pleadings alleging inferiority of grey market goods survive motion to strike

By May M. Cheng and Farai Munyurwa

This article was originally published on Law360 Canada on July 17, 2025, 10:58 AM EDT .
You can read the original article here.

The decision in Toyota Jidosha Kabushiki Kaisha (c.o.b. Toyota Motor Corp.) v. Marrand Auto Inc., 2025 FC 1105, issued on June 18, 2025, by Justice Janet Fuhrer, upheld a decision by Associate Judge Trent Horne that barely allowed the claim to survive a motion to strike. The decision appealed from had struck out the entire amended statement of claim with leave to amend only the claims advanced under paras. 7(b) and 22 of the Trademarks Act (TMA).The remaining claims under the Competition Act and s. 7(c) of the TMA were struck without leave to amend (see decision appealed from at Toyota Jidosha Kabushiki Kaisha (c.o.b. Toyota Motor Corp.) v. Marrand AutoInc., [2024] F.C.J. No. 2505.)

Justice Fuhrer makes the following query at the outset of her appeal decision on the motion to strike: “When is a TOYOTA bumper no longer a TOYOTA brand product? When it is damaged during shipment by a grey marketer, according to the Plaintiffs. Not so fast, says the Defendant.”

For those around long enough to recall the unsatisfying Supreme Court of Canada’s decision in Consumers Distributing Co. v. Seiko Time Canada Ltd., [1984] S.C.J. No. 27, where the court elected not to determine whether grey market goods could be deemed inferior when sold without the manufacturer’s warranty, this case raises the spectre of a definitive ruling on this elusive topic that has not been the subject of a decision in the 40 years since.

It should be remembered that in Seiko, Consumers Distributing was supplying a warranty card and made clear to customers that it was not an authorized dealer, so there were no false and misleading statements by the distributor as to the provenance of the goods, which were admitted to be genuine but simply diverted goods, and there was in fact a warranty provided, so this made it more difficult to allege inferiority based on lack of a warranty.

Justice Fuhrer’s decision is a terrific read as a definitive current summary of the legal elements required to establish a passing-off action, which she concludes very much still requires “use.” On this point, Justice Fuhrer found a palpable, but not overriding, error in Associate Judge Horne’s analysis. She nevertheless disagrees with Associate Judge Horne that any case law supports the proposition that passing off can be claimed in the absence of use and firmly makes the case with reference to a number of recent decisions including Justice Glennys McVeigh’s recent decision in 2K4 Inc. (c.o.b. Indican Pictures) v. Indiecan Entertainment Inc., 2025 FC 20 at para. 127. The result is an error that is palpable, but not overriding, in Justice Fuhrer’s estimation.

The court’s analysis concerning the legality of grey market goods remains the same as determined by Justice Nicholas McHaffie in the earlier decision of TFI Foods Ltd. v. Every Green International Inc., 2021 FC 241 at para. 50, which clearly states that “the sale in Canada of grey market goods does not, in itself, constitute passing off.” However, the TFI Foods decision did not decide the question left unanswered by Seiko because the conduct complained of was material misrepresentations as to being an “authorized distributor in Canada” for the grey goods. The interlocutory injunction and subsequent summary judgment granted in the TFI Foods case were limited to holding these were actionable false representations as to the status of the distributor. There was no allegation of lack of warranty or inferior quality of the goods arising from their grey goods status.

In this case, the defendant, Marrand Auto Inc., a reseller of grey market automobile components, was sued by a number of Toyota entities in Canada (collectively, “Toyota”) after a shipment of automotive parts bearing TOYOTA trademarks was detained by the Canada Border Services Agency.
Toyota inspected the goods and determined they were not counterfeit, but it claimed the parts were:

  • “Unauthorized,” as they lacked Toyota’s standard warranty;
  • Not sourced through authorized dealers; and
  • Damaged during shipment, allegedly compromising consumer safety.

If these allegations can be shown to be true in Marrand, the question remains as to whether this is merely allowed as part of the sale of diverted goods or whether this scenario presents sufficient concerns that courts will intervene to prevent the sale of grey goods. The case also has implications for “upcycled” goods that may also fall under the same shadow for no longer having the warranty of the original seller and which may be damaged during refurbishment.

While finding that Seiko differs factually from the case in Marrand, Justice Fuhrer indicated that Associate Judge Horne did not err in refusing to conclude that the current claim is doomed to fail, even in the absence of false or misleading representations by the defendant about the grey goods. Further, the s. 22 TMA claim concerning potential depreciation of goodwill remains arguable on the principle that the sale of damaged merchandise could be treated differently than a simple resale.

In the result, the Marrand case was allowed to proceed, and a fresh Amended Statement of Claim
had already been served at the time the appeal was argued. This case will be one to follow on
whether the law on grey goods is modified to allow manufacturers to take a harder line on diverted
goods that are nevertheless genuine. We have waited a whole 40 years, but it may finally be time for
the courts to revisit Seiko

 

Default Happens: A Practical Guide at Lender’s Rights and Remedies

By Gregory M. Prekupec & Rahul Gupta

Events of default occur by the existence of a certain action or omission which violates an aspect of an underlying loan agreement. Such event enables the lender to declare the same and to subsequently enforce its rights and remedies to make itself whole, as much as possible.

However, for a variety of reasons, lenders are often willing to negotiate with defaulted borrowers, for instance, by providing them with additional time to cure the default(s). As such, if the borrower is able to cure the default, then the loan agreement can resume.

The underlying loan agreement will provide the violations which would constitute an event of default, which ordinarily include the borrower ceasing its operations, the borrower’s failure to pay any principal amount or to perform any obligation under the loan agreement, the commencement of any bankruptcy or reorganization proceedings, and so on.

Lender Remedies

As mentioned above, the occurrence of an event of default can entitle the lender to pursue its rights and remedies under the underlying loan agreement. There are four general routes available to a lender when dealing with a defaulted borrower:

A. Performance of the remedies afforded to the lender pursuant to the underlying loan agreement;

B. Litigation to enforce the same;

C. Advancement under the Personal Property Security Act (Ontario) (“PPSA”), and,

D. Advancement under the Bankruptcy and Insolvency Act (Canada).

Each of these four remedies will be explored in greater detail below. A lender may have additional recourse should the borrower’s subsidiaries, affiliates, shareholders, or other entities also be party to the loan agreement.

Enforcement of Contractual Remedies

As an underlying rule, even if such loan agreement does not necessitate the borrower being notified of enforcement activity, notice is nonetheless required.

Depending on the extent of the event of default, a lender will likely commence by providing the borrower with a notice of default or demand letter which explains the nature of the default and any cure periods being afforded to the borrower. Subsequently, if the borrower fails to satisfy any arrears or omissions pursuant to any granted cure period, the lender can do any of the following: refuse to make future loan advances (depending on the structure provided in the loan agreement), terminate the loan agreement, or accelerate the loan.

A. Future Loan Advances

Loan advances are contingent upon the borrower’s compliance with all aspects of the loan agreement. As such, the occurrence of an event of default enables a lender to refuse to make any further loan advances. Syndicated credit facilities are similar such that each lender in the syndicate would refuse the extension of further credit.

Well-drafted loan agreements would trigger certain covenants upon an event of default, such as prohibiting a borrower from issuing dividends or pausing all acquisition activity. These remedies, particularly when combined, can have a devastating effect on the borrower’s business operations, which should incentivize immediate compliance with the loan agreement and cooperation with the lender(s).

B. Termination

Loan agreements afford lenders two additional remedies upon an event of default: the termination of any existing commitments for future loans and the acceleration of all amounts due, including any associated costs. The latter will likely be structured as an automatic remedy which would not require the lender providing additional for the same.

C. Acceleration

Acceleration is the automatic and immediate obligation of the borrower to pay all outstanding loan amounts and all associated costs. The borrower’s non-compliance with the same empowers the lender to enforce its rights through litigation or compel the borrower into bankruptcy or insolvency proceedings.

Despite the above, lenders often do not use this remedy as it would allow other lenders to also accelerate their loan, which increases the likelihood the borrower filing for bankruptcy. Lenders may, however, consider this remedy attractive if the borrower’s bankruptcy or insolvency is inevitable or the lender has lost faith in the borrower’s principals operating the business in a commercially reasonable fashion.

Alternative Remedies

As mentioned above, lenders may wish to negotiate with the borrower instead of immediately declaring an event of default. As such, lenders and borrowers may be able to negotiate for:

A. a waiver of the event of default;

B. the lender and borrower entering into a forbearance agreement where the lender will not declare an event of default for a certain time period;

C. amending the loan agreement;

D. an equity cure, where the borrower can receive an equity injection from its shareholder(s) to be provided for the funds required to settle any arrears; or

E. the requirement the borrower divest from its subsidiaries.

As a matter of commercial practicality, it is best practice for borrowers to remain transparent with their lenders throughout the lifecycle of the loan agreement. This creates an open and collaborative environment which invites the possibility of reasonable compromises rather than automatic deference to litigation or bankruptcy/insolvency proceedings. However, this is not to excuse the lender conducting comprehensive reviews of the borrower’s operations upon the occurrence of an event of default to confirm the borrower’s financial viability moving forward.

Additional Considerations

Regardless of the avenue a lender decides to pursue in regards to a defaulted borrower, it must consider all aspects, including the ones listed below.

A. Default Interest

Loan agreements include default interest provisions which charge a certain interest rate on the outstanding amount and is incurred until the lender is made whole.

B. Letters of Credit

An event of default leads to no additional letters of credit being issued. In addition, the lender may require the borrower provide a cash deposit to be used as additional collateral. The borrower refusing which would entitle the lender to claim such amount against the borrower during legal proceedings.

C. Set Off

The lender can off set any deposit it holds from the borrower and use such funds to repay a portion of the defaulted loan.

D. Guarantors

If the loan agreement provides for a guarantee from a corporate affiliate of the borrower, or a personal guarantee of the borrower’s director(s), then the lender is entitled to treat the guarantor as the borrower. In other words, the lender can enforce its rights against any or all of the borrower(s) and guarantor(s). However, this would also require the guarantor receive the same notices as the borrower.

E. Collateral

If the loan agreement provides for a guarantee from a corporate affiliate of the borrower, or a personal guarantee of the borrower’s director(s), then the lender is entitled to treat the guarantor as the borrower. In other words, the lender can enforce its rights against any or all of the borrower(s) and guarantor(s). However, this would also require the guarantor receive the same notices as the borrower.

F. Enforcement Issues

There are a number of enforcement-related issues which may arise.

First, there may be other creditors, including government agencies such as the Canada Revenue Agency, which also have amounts owing to them. Therefore, a lender must understand its order in repayment priority. For instance, tax arrears can carry a supermajority such that they override all other secured claims. It is also important to determine the existence of intercreditor agreement(s) and subordination agreement(s). In so doing, senior lenders may be prioritized over subordinated creditors or the senior lender may be limited in its enforcement abilities.

Second, if the borrower operates in a number of jurisdictions, the lender must understand the procedural issues, if any, it will have to undergo to enforce the loan agreement.

Conclusion

In navigating the complex landscape of lender enforcement, it is critical for lenders to adopt a strategic and legally sound approach when responding to borrower defaults. From out-of-court workouts and enforcement under the PPSA, to formal insolvency proceedings and actions against guarantors or collateral, each remedy must be exercised with consideration of its implications, procedural requirements, and the overarching duty of good faith. A well-drafted loan agreement—paired with proactive monitoring and clear communication—remains a lender’s most powerful tool. By understanding and leveraging the full spectrum of remedies available under the law, lenders can not only protect their financial interests but also promote constructive resolutions that mitigate risk and preserve long-term value.

 

 

 

This article was informed by Practical Law Canada and industry practice.

Eculizumab Patent Valid and Infringed by Amgen

By Christopher Tan & Alexander Watts

On May 12, 2025, the Federal Court allowed Alexion’s action under the Patented Medicines (Notice of Compliance) Regulations in relation to the drug eculizumab (Alexion’s SOLIRIS®). Alexion had alleged that Amgen infringed Claims 1 and 2 (the “Asserted Claims”) of Canadian Patent No. 2,645,810 (the “810 patent”), entitled “Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients by an Inhibitor of Complement”. Amgen admitted infringement of the Asserted Claims, but in defence, alleged that the 810 Patent was invalid for anticipation and/or obviousness. Justice Furlanetto found that Amgen did not establish that the Asserted Claims are invalid for either anticipation or obviousness: Alexion Pharmaceuticals, Inc v Amgen Canada Inc, 2025 FC 754.

Practice highlights from this case

  • Strict Limits on Incorporation by Reference Reinforce the Single-Document Rule for Anticipation
    The Court reaffirmed that for anticipation to be established, a single prior art reference must disclose the claimed invention clearly and completely, unless a secondary source is expressly incorporated with specific direction. The burden to show that information from a second source would actually be consulted by the skilled person is on the party seeking to use the second source.
  • An intention to disclose before filing is not equivalent to an actual invalidating disclosure
    Alexion’s submission and disclosure of an eculizumab sequence did not amount to an enabling public disclosure, as the deposited sequence contained significant errors and there was no evidence that further inquiries by a skilled person would have been routine practice.
    A party seeking to rely on prior art that was intended for disclosure but never actually disclosed, must show that the skilled person, using the common general knowledge, could derive the error from the prior art document and would attempt to make further inquiries into correcting the error.
    The reverse scenario — where an enabling disclosure is made unintentionally or by mistake — is still invalidating. This includes situations where disclosures are made to third parties without any restrictions that would prevent the information from entering the public domain, such as those typically imposed by a formal confidentiality agreement or joint venture arrangement (see g., Wenzel Downhole Tools Ltd v National-Oilwell Canada Ltd, 2011 FC 1323 at paras 138, 142).

Background

SOLIRIS is an intravenously administered biologic drug containing eculizumab as its active ingredient. Eculizumab is a recombinant humanized monoclonal antibody, which is used to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that causes the breakdown of red blood cells. SOLIRIS prevents cleavage and the terminal complement pathway from attacking abnormal red blood cells by binding to complement protein C5, thereby protecting red blood cells from lysing and, as a result, stabilizing hemoglobin levels.

The 810 Patent is listed on the Patent Register against SOLIRIS. As such, Amgen (and any other party seeking to market a biosimilar eculizumab drug product in Canada) is required to address the 810 Patent (and any other patent listed on the Patent Register) by either establishing that the patent(s) will not be infringed and/or that the patent(s) is invalid.  The 810 Patent was filed on March 15, 2007, published on September 20, 2007, issued on December 11, 2018 and will expire on March 15, 2027.  Although the 810 Patent has a priority claim, Alexion did not seek to assert the priority date.  As such, the Court considered whether the 810 patent was anticipated or obvious as of March 15, 2007.

The 810 Patent states that in certain embodiments, the antibody that binds C5 has a heavy chain that consists of SEQ ID NO:2 and a light chain that consists of SEQ ID NO:4 (the full amino acid sequence is provided for both heavy and light chains). Together, these defined sequences correspond to the structure of eculizumab.

Asserted Claims

The 810 Patent includes 16 claims, only two of which were at issue; Claims 1 and 2 of the 810 Patent read as follows:

  1.  An antibody that binds C5 comprising a heavy chain consisting of SEQ ID NO:2 (“Heavy Chain Sequence”) and a light chain consisting of SEQ ID NO:4 (“Light Chain Sequence”).
  2.  A pharmaceutical composition comprising the antibody of claim 1 and a carrier.

Anticipation

Amgen asserted that Claims 1 and 2 are anticipated by United States Patent Application Publication No. 2003-0232972 (“US972”), which claims the use of antibodies as a structural framework to provide mimetic peptides with enhanced stability. US972 discloses both a light chain and heavy chain sequence which is the same as the Light Chain Sequence and Heavy Chain Sequence of eculizumab, respectively, except that the native complementarity determining region (“CDR3”) of the heavy chain was substituted for a thrombopoietin mimetic peptide.

While it was not disputed that US972 does not disclose the full sequence of eculizumab, Amgen argued that the skilled person would look to US Patent No. 6,355,245 (“US245”) — which is cited in both the 810 Patent and US972 — as teaching the humanized constructs of the native CDR3 region for binding C5. According to Amgen, transplanting the CDR3 sequence from US245 into the antibody scaffold disclosed in US972 would result in eculizumab. Alexion disagreed, maintaining that US972 does not direct the skilled person to reconstruct eculizumab and that its preparation is not a necessary outcome of following US972’s teachings.

Alexion also took issue with Amgen’s reliance on US245 as part of the teaching of US972 and argued that eculizumab is not necessarily made in the preparation of the US972 antibody product. The Court noted that the critical factor for anticipation is whether the prior reference provides clear direction, such that the skilled person would arrive inevitably at the claimed invention.  Where an incorporation by reference is used, it will depend on what directions the primary source provides as to how the incorporated reference is to be used. It is only where the incorporation is explicit and directs the skilled person to specific teachings that are necessary to complete the disclosure that more than one publication may be deemed a single prior publication. This reinforces the long-standing prohibition against ‘mosaicking’ prior art in anticipation analyses and clarifies that incorporation by reference depends “on what directions are provided in the primary source as to how the incorporated reference is to be used.” The Court held that Amgen’s approach was akin to using incorporation by reference to mosaic information from US245 with teachings from US972 due to the lack of clear direction.

Amgen’s reliance on US245 was inconsistent with the requirement that anticipation be based on a single disclosure, as US972 alone did not meet the standard for enabling disclosure. The Court emphasized that US972 did not instruct the skilled person to use a “reverse cloning” approach to recreate eculizumab and agreed that, while it might be possible to produce eculizumab using the patent’s teachings, “this approach would only arise as a matter of hindsight” in the mind of the skilled person. Accordingly, US972 did not provide the clear and unambiguous disclosure required to anticipate the claims of the 810 Patent.

Obviousness

As eculizumab was known by the claim date to selectively bind C5, the Court accepted that the inventive concept of Claim 1 was the identification of eculizumab’s specific Heavy Chain Sequence and Light Chain Sequence. The inventive concept of Claim 2 is the formulation of the antibody of Claim 1 into a pharmaceutical composition so that it can be delivered to a patient to provide the intended therapeutic effect.

As part of the state of the art, numerous publications and disclosures were reviewed by the Court, including Alexion’s depositing — without any obligation of confidentiality — of what it thought was the correct amino acid sequence for eculizumab with the Chemical Abstract Service (“CAS”).  However, this CAS sequence included significant errors. As a result, while the Court agreed that the evidence indicates that Alexion wanted to disclose the sequence of eculizumab to the public as early as 1999, by depositing a sequence that had errors, it did not do so. Expert evidence about whether the skilled person would have inquired with CAS or Alexion about the sequences was not before the Court, though it was apparent the skilled person could have done so. Alexion’s intention to disclose was therefore found to be distinct from actual disclosure.

The Court concluded that from the state of the art, the skilled person would have known that Alexion had a drug named eculizumab, which was associated with the humanized murine monoclonal antibody 5G1.1, selective for C5, and being used to treat patients with PNH. The Court concluded however, that none of the prior art disclosed both the Heavy Chain Sequence and Light Chain Sequence.

The Court therefore held that, although the prior art described components of similar antibodies, the prior art did not demonstrate a clear and obvious path to the claimed invention. Justice Furlanetto concluded that the PSA would not have been led, without hindsight, to select and combine the prior art references to reconstruct eculizumab’s precise structure. In particular, the Court noted the absence of disclosure or suggestion in the prior art connecting the specific sequences of Claim 1 with therapeutic success. As such, the skilled person would not be able to bridge the differences between the state of the art and the claimed invention using only routine skill and the common general knowledge such that the Asserted Claims were found to be non-obvious.

Conclusion

In summary, the Court determined that the Asserted Claims of the 810 Patent were both valid and infringed. Justice Furlanetto dismissed Amgen’s arguments relating to anticipation and obviousness in their entirety.

Amgen has appealed the decision to the Federal Court of Appeal (Court File No. A-207-25).

 

Should you have any questions, please do not hesitate to contact a member of Dipchand, LLP.

This article is provided for informational purposes only and does not constitute legal or professional advice. Readers should not act or refrain from acting based solely on the contents of this publication. The qualified legal professionals at Dipchand, LLP would be pleased to assist with any legal inquiries related to this topic.

 

 

Thomson Reuters Enterprise Centre GMBH v Ross Intelligence Inc – Creators Enjoy a Win in the Non-Generative AI Battle, but the Outcome of the War is Far from Clear and Nowhere Near Over

Thomson Reuters Enterprise Centre GMBH v Ross Intelligence Inc – Creators Enjoy a Win in the Non-Generative AI Battle, but the Outcome of the War is Far from Clear and Nowhere Near Over

By: Elizabeth S. Dipchand and Zach Nickels 

At a time of considerable uncertainty surrounding the exponential intersection of copyright and AI development, a landmark copyright decision coming from the United States District Court for the District of Delaware represents a significant win for copyright owners, and reinforces the significant control that copyright owners have over their copyright protected works.

On February 11, 2025, the Court granted summary judgment in favour of the Plaintiff Thomson Reuters in the first fair use case involving non-generative artificial intelligence (“AI”), revising a previous 2023 summary judgment opinion and order in the case.

The potential for this decision to set a trend makes it imperative for AI developers to carefully consider how they engage copyright owners and their works in order to avoid liability. This will likely include comprehensive and clear licence arrangements explicitly covering use in training models; alternatively, risks can be significantly mitigated by relying solely on works in the public domain. However, the question as to whether a fair use defence analysis would result differently in the context of generative AI, wherein the impugned use is found to be transformative in nature, still remains unclear.

Reconsideration of Summary Judgement Order

In his decision, Circuit Judge Stephanos Bibas noted that he had previously largely denied Thomson Reuters’ motions for summary judgment on copyright infringement and fair use defence, but in the lead up to the August 2024 trial date revisited the case materials and realized that the prior summary judgment ruling had “not gone far enough”. Judge Bibas invited the parties to renew their summary judgment briefings, and in his decision:

  • Granted most of Thomson Reuters’ motion for partial summary judgment on direct copyright infringement and related defenses;
  • Granted Thomson Reuters’ motion for partial summary judgment on fair use;
  • Denied Ross Intelligence’s motion for summary judgment on fair use; and
  • Denied Ross Intelligence’s motion for summary judgment on Thomson Reuters’ copyright claims

Working Around Westlaw

Thomson Reuters Enterprise Centre GMBH (“Thomson Reuters”) owns Westlaw, one of the largest legal-research platforms commonly used by lawyers and law students. For the payment of subscription fees, Westlaw provides its users access to case law, statutes, law journals and treatises among other content, all of which is organized using a “Key Number System”. Westlaw also provides editorial content such as headnotes (“Headnotes”) which summarize the case law and key findings. Thomson Reuters owns the copyright in Westlaw’s copyright protected material.

Ross Intelligence Inc. (“Ross”) is a new competitor on the market, which offers a legal-research search engine that uses AI. In the events leading up to this dispute, Ross needed a database of legal questions and answers to “train” its AI search tool and asked to license Westlaw’s content. Thomson Reuters refused this request because Ross was a competitor.

To circumvent this roadblock and train its AI, Ross entered into a deal with LegalEase to access training data in the form of “Bulk Memos”, which were lawyers’ compilations of legal questions with good and bad answers. LegalEase provided the lawyers that created the Bulk Memos with a guide on how to create the questions using Westlaw’s Headnotes. In essence, Ross trained its AI on the Bulk Memos, which were built themselves from Thomson Reuters’ Headnotes. As such, the Court described the dispute as boiling down to whether the LegalEase Bulk Memo questions copied the Headnotes, or were instead taken from uncopyrightable judicial opinions.

At Issue… Again

  • Direct Copyright Infringement

In assessing whether Ross directly infringed Thomson Reuters’ copyrights, the Court considered whether Thomson Reuters owned a valid copyright, and whether Ross copied protectable elements of the copyrighted works. The second element required the Court to determine whether Thomson Reuters had shown that Ross actually copied the works, and that the copying was substantially similar to the works at issue.

Thomson Reuters’ Copyrights are Original and Valid

With respect to the validity of Thomson Reuters’ copyrights, the Court recognized that originality is central to copyright and a low threshold to meet, only requiring some minimal degree of creativity. The pertinent question is whether a work is original, not how much effort went into creating it. The Court found that the Headnotes and Key Number System met the minimal threshold for originality, satisfying the first element.

Ross Copied Protectable Elements of the Copyrighted Works

With respect to whether Ross copied protectable elements of the copyrighted works, the Court considered whether there was copying of the constituent elements of the works that were original, deciding whether Thomson Reuters had proven both actual copying and substantial similarity. The Court applied the actual copying and substantial similarity analyses to a subset of 2,830 Headnotes and found actual copying of 2,243 of them. However, the Court reached no new decision on the Key Number System as factual disputes remained as to whether Ross had actually used it.

  1. Actual Copying

Actual copying means that a defendant did in fact use the copyrighted work in creating the impugned work. This can be proved directly, through evidence that the defendant copied the work, or indirectly, by showing the defendant had access to it and produced something similar.

In its decision, the Court compared how similar 2,830 Bulk Memos, Headnotes and judicial opinions were one by one, acknowledging that LegalEase had access to Westlaw and used it to create the Bulk Memos, while noting that access alone is not proof of copying. The Court further observed that in instances where a Bulk Memo question looked more like a Headnote than an underlying judicial opinion there was strong circumstantial evidence of actual copying.

Upon the Court’s review of the 2,830 Headnotes, they granted summary judgment to Thomson Reuters on actual copying on 2,243 of them – a subset of which actual copying was so obvious that no reasonable jury could find otherwise.

  1. Substantial Similarity

The substantial similarity analysis requires an evaluation of whether the latter work materially appropriates the copyrighted work, and involves a consideration of which parts of the actually copied work are original expressions protected by copyright. In considering this, the Court noted that the question is whether an ordinary user of a product would find it substantially similar to the copyrighted works.

Ross argued that the Bulk Memo questions had to not just be substantially similar to the Headnotes, but virtually identical due to the “thin” nature of the Headnotes’ underlying copyrights. Effectively, the less protectable expression a work contains, the more similar the impugned work must be to it.

Applying this standard, the Court granted summary judgment on substantial similarity on 2,243 Headnotes, finding that the Bulk Memo questions were substantially similar to them. In this regard, the Court specified that it granted summary judgment only on the Headnotes whose language “very closely track[ed] the language of the Bulk Memo question but not the language of the case opinion”.

  • Ross Defenses to Copyright Infringement Failed

The Court rejected all of Ross’ defenses of innocent infringement, copyright misuse, merger and scenes a faire.

The Court summarily dismissed Ross’ claim that any infringement was innocent. The defence of innocent infringement acts to only limit damages, as opposed to liability. However, Thomson Reuters’ Headnotes included a copyright notice, and as such innocent infringement did not apply.

The Court also dismissed Ross’ argument that Thomson Reuter misused its copyright, alleging it weaponized its copyright against the public interest, a form of “anti-competitive behaviour”. The Court disagreed with this contention, and found that Ross had not shown that Thomson Reuters misused its copyrights to “stifle competition”.

Ross further claimed the defense of merger, alleging that any ideas embodied in the Headnotes were so close to the expressions that they merged with the expressions themselves, in turn making the Headnotes uncopyrightable. The Court rejected this defense, having found that copyright subsisted in the Headnotes and holding that there were a variety of ways to express points of law from judicial opinions.

The Court also rejected Ross scenes a faire defence, which concerns “stock elements that follow from the work’s nature” – essentially, common tropes associated with a work. In this regard the Court observed that “nothing about a judicial opinion requires it to be slimmed down” in the same manner as Thomson Reuters’ Headnotes.

  • Thomson Reuters Prevailed on Fair Use

In assessing Ross’ claims of fair use, the Court considered the four factors required to establish the defence of fair use, including:

  • the use’s purpose and character, including whether it was commercial or nonprofit;
  • the nature of the copyrighted work;
  • how much of the work was used and how substantial a part it was relative to the copyrighted work’s whole; and
  • how Ross’ use affected the copyrighted work’s value or potential market.

Although fair use is a question of mixed fact and law, the Court held that the undisputed facts of the case pushed it “squarely into the legal realm” such that the fair use question was appropriate for a judge to determine and not a jury.

The Court ultimately held that Thomson Reuters prevailed on factors 1 and 4, the two most important factors, and on the factors’ overall balancing.

Factor 1 – The Use’s Purpose and Character was Commercial and Non-Transformative

With respect to the first factor, Court found that Ross’ use was commercial in nature and not transformative. The Court recognized Ross’ admission that it stood to profit from the exploitation of the copyright protected material without paying the customary price, and was commercial in nature.

The Court further found that Ross’ use was not transformative as it did not have a “further purpose or different character” from the Thomson Reuters’ Headnotes. However, Ross argued that because the Headnotes did not appear as part of Ross’ final product, the copying therefore occurred at intermediate steps, and that intermediate copying had been permitted under the first fair use factor in prior decisions concerning computer programs.

The Court rejected this contention, distinguishing the case from previous intermediate-copying decisions on the basis that computer programs differ from other literary works as computer programs always serve a functional purpose, and that intermediate-copying in such cases was necessary for the competitors to innovate. In the present case, the copying was not found to be reasonably necessary to achieve Ross’s new purpose.

Bad Faith Irrelevant and Immaterial

Due to Ross’ commercial and non-transformative use, the Court did not consider whether Ross had acted in bad faith.

Factor 2 – The Headnotes Had Minimal Creativity  

The Court’s analysis on the nature of the original work focused on the degree of creativity inherent to the Headnotes. It found that Thomson Reuters’ material had more than the minimal spark of originality required for copyright to subsist, but that the Headnotes were not especially creative. As such, the Court found in Ross’ favour on this factor, but qualified this finding noting that the second factor “rarely play[s] a significant role in the determination of a fair use dispute”.

Factor 3 – Ross’ Use Did Not Constitute a Substantial Part Relative to the Whole of the Headnotes

Under factor 3 of the analysis, the Court assessed whether Ross’ use was “reasonable in relation to the purpose of the copying”, considering the “quantity of the materials used’ and “their quality and importance”. The question core to this analysis was whether Ross had copied the “heart” of the works at issue.

In undertaking the analysis, the Court noted that what matters is the amount and substantiality of what was made accessible to a public which may serve as a substitute. As Ross did not make the Headnotes available to the public, the Court found in Ross’ favour.

Factor 4 – Ross’ Use Affected the Headnotes’ Value or Potential Market

Under the fourth factor, the Court found in favour of Thomson Reuters, holding that Ross meant to compete with Thomson Reuters by creating a market substitute, and that Ross had not put forward sufficient facts to show that a potential market for AI training data did not exist and would not be affected by Ross’ use.

With respect to Ross’ arguments concerning the public interest, the Court further found that public interest in the subject matter at issue alone was insufficient, and that the public had no right to Thomson Reuters’ “parsing of law”.

The Court’s Findings

The Court ultimately held that Ross had infringed 2,243 Headnotes (and the only remaining factual issue was whether some of their copyrights had expired) and that Ross’ innocent infringement, copyright misuse, merger and scenes a faire defenses all failed.

Key Takeaways

While uncertainty remains as to how Canadian courts would decide a similar case, this decision may be an indication of the perils of training AI on copyright protected works. In any event, the decision reinforces the protections conferred by copyright ownership and serves as a reminder of the importance of entering into valid licensing agreements before training AI on copyright protected works.

Skip to content